GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Asset Turnover

EV Biologics (EV Biologics) Asset Turnover : 0.84 (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. EV Biologics's Revenue for the three months ended in Dec. 2017 was $38.72 Mil. EV Biologics's Total Assets for the quarter that ended in Dec. 2017 was $46.12 Mil. Therefore, EV Biologics's Asset Turnover for the quarter that ended in Dec. 2017 was 0.84.

Asset Turnover is linked to ROE % through Du Pont Formula. EV Biologics's annualized ROE % for the quarter that ended in Dec. 2017 was -38.98%. It is also linked to ROA % through Du Pont Formula. EV Biologics's annualized ROA % for the quarter that ended in Dec. 2017 was -19.42%.


EV Biologics Asset Turnover Historical Data

The historical data trend for EV Biologics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Asset Turnover Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Asset Turnover
0.74 0.70 0.63 0.75 0.27

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 1.22 - 0.84

Competitive Comparison of EV Biologics's Asset Turnover

For the Biotechnology subindustry, EV Biologics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where EV Biologics's Asset Turnover falls into.



EV Biologics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

EV Biologics's Asset Turnover for the fiscal year that ended in Jun. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2017 )/( (Total Assets (A: Jun. 2016 )+Total Assets (A: Jun. 2017 ))/ count )
=9.507/( (36.443+33.278)/ 2 )
=9.507/34.8605
=0.27

EV Biologics's Asset Turnover for the quarter that ended in Dec. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2017 )/( (Total Assets (Q: Jun. 2017 )+Total Assets (Q: Dec. 2017 ))/ count )
=38.723/( (33.278+58.954)/ 2 )
=38.723/46.116
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


EV Biologics  (OTCPK:YECO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

EV Biologics's annulized ROE % for the quarter that ended in Dec. 2017 is

ROE %**(Q: Dec. 2017 )
=Net Income/Total Stockholders Equity
=-8.956/22.9765
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-8.956 / 154.892)*(154.892 / 46.116)*(46.116/ 22.9765)
=Net Margin %*Asset Turnover*Equity Multiplier
=-5.78 %*3.3587*2.0071
=ROA %*Equity Multiplier
=-19.42 %*2.0071
=-38.98 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) net income data. The Revenue data used here is four times the quarterly (Dec. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

EV Biologics's annulized ROA % for the quarter that ended in Dec. 2017 is

ROA %(Q: Dec. 2017 )
=Net Income/Total Assets
=-8.956/46.116
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-8.956 / 154.892)*(154.892 / 46.116)
=Net Margin %*Asset Turnover
=-5.78 %*3.3587
=-19.42 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) net income data. The Revenue data used here is four times the quarterly (Dec. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


EV Biologics Asset Turnover Related Terms

Thank you for viewing the detailed overview of EV Biologics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics Updates on Funding and Sales

By ACCESSWIRE 10-02-2023

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics NFT Dividend Warrant Date

By ACCESSWIRE ACCESSWIRE 07-30-2021

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021